Free Trial

Iterum Therapeutics Q3 2023 Earnings Report

Iterum Therapeutics logo
$1.77 +0.02 (+1.14%)
(As of 12/20/2024 05:45 PM ET)

Iterum Therapeutics EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.91
Beat/Miss
Beat by +$0.61
One Year Ago EPS
N/A

Iterum Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Iterum Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Iterum Therapeutics Earnings Headlines

Iterum Therapeutics Regains Full Nasdaq Compliance
Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Iterum Therapeutics sees cash runway into 2025
See More Iterum Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iterum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iterum Therapeutics and other key companies, straight to your email.

About Iterum Therapeutics

Iterum Therapeutics (NASDAQ:ITRM), a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

View Iterum Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings